Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02381392 · ClinicalTrials.gov registry record · NA

A Comparison of Accuvein to Standard IV Access in Children 0 to 24 Months of Age in the Pediatric ED

A NA study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

Terminated
Registry status
NA
Development phase
23
Enrollment target

NCT02381392: Clinical Trial NA study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

NCT02381392 is a NA study that was terminated before completion, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02381392, a NA study, was terminated before completion, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

TERMINATED
Registry status
NA
Development phase
23 participants
Enrollment target

Study Summary

Obtaining intravenous (IV) access in children under the age of 2 years is difficult, especially in the emergency department (ED) where the children can be frightened, dehydrated and ill. Often it requires multiple needle sticks and nurses to place an IV in a difficult child. In our ED the recently acquired an Accuvein AV400 device. This infrared light, like a barcode scanner, makes the veins on a child appear like roads on a map. This ideally shows the nurse where to place and direct the needle. This device is approved by the FDA to work with children and has not been shown to have any harmful effects. However, there are no studies showing whether this device helps in the difficult less than 2 year olds seen in the emergency department. This study will be to directly compare placing an IV in a child under 2 years of age with the AV400 versus not using the device. A physician, medical student, or nurse practitioner who has been trained on how to observe nurses place IVs will enroll children who require an IV for their ED clinical care (as determined by their ED doctors). This person will consent the parents, ask the parents questions regarding the child's past medical history, and have the nurse look at the veins of the child ahead of the IV access attempt to rate the level of difficulty expected (easy, moderate, difficult). Whether the child has the IV attempt performed with or without the AV400 will be computer randomized. The nurse will attempt to place the IV, and the study staff will observe and record the number of attempts, size of the IV catheter, and location of the IV. If 2 attempts are failed, the patient will "cross over" to the other condition, that is if AV400 was being used then it will not be used, and if AV400 was not being used then it will be used. If there are 4 failed attempts at IV placement, then the child will be treated as per our department's difficult IV access protocol, which is applied to all children with difficult IV access regardless

Primary Outcome

Successful: Intravenous line successfully placed with blood able to be drawn back and fluid able to be flushed into the vein. Flashback but IV blown: blood initially successfully drawn back or seen in the syringe, but subsequently unable to flush fluid into the vein. No flashback: no blood drawn back into or seen in the syringe at all. Missing data: data not recorded regarding success or flashback.

Interventions

  • DEVICE Accuvein AV400

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2014-08
Est. Completion 2016-11-19
Phase NA

Why NCT02381392 stopped before completion

NCT02381392 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Accuvein AV400 is the first listed.

NCT02381392 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02381392 about?

NCT02381392 is a clinical study titled "A Comparison of Accuvein to Standard IV Access in Children 0 to 24 Months of Age in the Pediatric ED". Obtaining intravenous (IV) access in children under the age of 2 years is difficult, especially in the emergency department (ED) where the children can be frightened, dehydrated and ill. Often it requires multiple needle sticks and nurses to place an IV in a difficult child. In our ED the recently a...

What is the current status of trial NCT02381392?

This trial is currently terminated. It is a NA study. The enrollment target is 23 participants. The study started on 2014-08. Estimated completion is 2016-11-19.

What interventions are being tested in trial NCT02381392?

The interventions under investigation include: Accuvein AV400 (DEVICE).

Who is sponsoring clinical trial NCT02381392?

This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02381392's enrollment target sits among peer trials

23 1755th of 2000 higher than 245 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02381392, the US trial registry maintained by the National Library of Medicine. NCT02381392 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.